Intravesical IL-2
Bladder Cancer
Pre-clinicalActive
Key Facts
About Immunservice
Immunservice is a specialized biotech firm built around the therapeutic potential of interleukin-2 (IL-2). Founded as a spin-off from the University of Hamburg, it has a dual business model: supplying high-quality, ready-to-use IL-2 cell culture media and related services to the research community, while concurrently developing a proprietary pipeline of localized IL-2 immunotherapies for human and veterinary use. The company is led by founder and IL-2 pioneer Edith Huland and is backed by seed investor High-Tech Gründerfonds, positioning it as a niche player bridging research tools and clinical development in immunotherapy.
View full company profileOther Bladder Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Measovir®-based candidate | Oncovita | Pre-clinical |
| ADC Resistance in Bladder Cancer | Elucidate Bio | Research |
| Platin-DRP® | Chosa Oncology | Development |
| PanGIA Bladder | PanGIA Biotech | Pre-clinical |
| FGFR3 | Onco3R Therapeutics | Phase 1/2 |
| Urine-based Bladder Cancer Detection | Qurin Diagnostics | Pre-clinical |